Traders sold shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) on strength during trading on Friday. $10.80 million flowed into the stock on the tick-up and $30.59 million flowed out of the stock on the tick-down, for a money net flow of $19.79 million out of the stock. Of all equities tracked, Sage Therapeutics had the 0th highest net out-flow for the day. Sage Therapeutics traded up $2.27 for the day and closed at $97.71

Several analysts have recently weighed in on the company. Raymond James Financial, Inc. upped their price objective on Sage Therapeutics to $109.00 and gave the company a “buy” rating in a report on Thursday, November 9th. Chardan Capital upgraded Sage Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $60.00 to $140.00 in a report on Friday, November 10th. Needham & Company LLC upped their price objective on Sage Therapeutics from $86.00 to $100.00 and gave the company a “buy” rating in a report on Friday, November 10th. Leerink Swann upped their price objective on Sage Therapeutics from $85.00 to $123.00 and gave the company a “positive” rating in a report on Thursday, November 9th. Finally, Royal Bank Of Canada upped their price objective on Sage Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Thursday, November 9th. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Sage Therapeutics currently has an average rating of “Buy” and a consensus price target of $105.71.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($1.98) by $0.01. Sage Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. analysts forecast that Sage Therapeutics, Inc. will post -7.38 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in SAGE. BlackRock Inc. raised its position in Sage Therapeutics by 5.9% during the second quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock valued at $241,431,000 after buying an additional 168,424 shares during the period. Vanguard Group Inc. raised its position in Sage Therapeutics by 2.2% during the second quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock valued at $219,006,000 after buying an additional 58,679 shares during the period. Bank of New York Mellon Corp raised its position in Sage Therapeutics by 36.5% during the third quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock valued at $168,834,000 after buying an additional 724,494 shares during the period. State Street Corp raised its position in Sage Therapeutics by 7.7% during the second quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock valued at $96,558,000 after buying an additional 87,097 shares during the period. Finally, Oak Ridge Investments LLC raised its position in Sage Therapeutics by 0.9% during the third quarter. Oak Ridge Investments LLC now owns 736,709 shares of the biopharmaceutical company’s stock valued at $45,897,000 after buying an additional 6,835 shares during the period.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/investors-sell-sage-therapeutics-inc-sage-on-strength-sage/1726862.html.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.